

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051352 A1

(51) International Patent Classification⁷: A61K 31/34,
C07D 307/81, 307/82

(21) International Application Number: PCT/US02/38908

(22) International Filing Date: 5 December 2002 (05.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/340,361 14 December 2001 (14.12.2001) US

(71) Applicant (for all designated States except US): ALCON,
INC. [CH/CH]; P. O. Box 62, Bösch 69, CH-6331 Hünen-
berg (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MAY, Jesse, A.
[US/US]; 4132 Hildring Drive East, Fort Worth, TX 76109
(US).

(74) Agents: SCHULTZ, Teresa, J. et al.; Alcon Research,
LTD., R & D Counsel, Q-148, 6201 South Freeway, Fort
Worth, TX 76134-2099 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, SI, SK, TR).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW, European patent (AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, SI, SK, TR)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA

(57) Abstract: The present invention provides novel compounds, compositions containing the compounds of the invention in a
pharmaceutically acceptable excipient and methods for using the compositions for lowering intraocular pressure.

WO 03/051352 A1

AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS
FOR THE TREATMENT OF GLAUCOMA

5 BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to treatment for lowering intraocular pressure and to
10 compounds for use in such treatments. More particularly, the present invention relates to
the use of compounds with serotonergic 5-HT₅-HT₂ agonist activity to lower intraocular
pressure (IOP), treat glaucoma, and to provide neuroprotection.

15 2. Description of the Related Art

Serotonin (5-hydroxy tryptamine; 5-HT₅-HT) is an endogenous biogenic amine
with a well defined neurotransmitter function in many tissues of the body including the
eye [Zifa and Fillion 1992; Hoyer *et al.* 1994; Tobin *et al.* 1988].

20 5-HT is known to interact with at least seven major 5-HT receptors (5-HT₁ - 5-HT₇)
and additional subtypes within these families to initiate intracellular biochemical events
such as stimulation of second messengers (e.g. cAMP, inositol trisphosphate) eventually
leading to the final biological response, for example, tissue contraction or hormone
release, etc. [Hoyer *et al.* 1994; Martin *et al.* 1998]. Receptor subtypes within the 5-HT₁
25 family are negatively coupled to adenylyl cyclase (AC) and cause inhibition of cAMP
production, while 5-HT₄, 5-HT₆, and 5-HT₇ receptors are positively coupled to AC and
thus stimulate cAMP production when activated by 5-HT [Martin *et al.* 1998]. The
receptors in the 5-HT₂ family are positively coupled to phospholipase C (PLC) and thus

generate inositol phosphates and mobilize intracellular calcium when activated to mediate the effects of 5-HT. The 5-HT₃ receptor is unique in that it couples to an ion channel which gates sodium, potassium, and calcium [Hoyer *et al.* 1994].


5 The human and animal 5-HT₇ receptor has only recently been cloned, expressed, and shown to be present in various brain areas and peripheral tissues [Eglen *et al.* 1997]. Recent studies have shown there to be four splice variants of the 5-HT₇ receptor [Heidmann *et al.* 1997]. It has been proposed that the 5-HT₇ receptor may be involved in the pathophysiology of sleep disorders, depression, and other psychiatric disorders [Eglen
10 *et al.* 1997]. In the periphery, stimulation of 5-HT₇ receptors results in relaxation of blood vessels and hence vasodilation [Eglen *et al.* 1997].

Known compounds exhibiting 5-HT₂ agonist activity have typically been designed to treat numerous central nervous system (CNS)-related conditions, particularly the
15 treatment of obesity and depression, by activation of 5-HT_{2C} receptors. Thus, one desired property of known 5-HT₂ agonist compounds is that they easily penetrate the blood brain barrier. Compounds possessing the property of penetration into the CNS generally do not contain polar groups.

20 To treat ocular diseases, it is desirable to administer compositions orally or topically that will remain in the ocular tissues and not cross the blood brain barrier to enter the CNS. What are needed are 5-HT₂ agonist compounds that are useful in the treatment of ocular diseases characterized by an elevated intraocular pressure, the treatment of glaucoma and neuroprotection. Such compounds would not have a propensity to cross the
25 blood brain barrier.

SUMMARY OF THE INVENTION

The present invention overcomes these and other drawbacks of the prior art by
 5 providing compounds having 5-HT₂ agonist activity that do not cross the blood brain
 barrier. More specifically, the present invention provides compounds having the following
 general formula:



wherein R¹ is hydrogen or C₁₋₄alkyl; R² is hydrogen, C₁₋₄alkyl, or R¹ and R² can together be
 10 (CH₂)₂₋₄ to complete a heterocyclic ring; R³ is hydrogen, hydroxyl, C₁₋₄alkoxy, or fluorine;
 R⁴ is selected from C₁₋₄alkyl, halogen, nitrile, C₁₋₆alkylthiol, trifluoromethyl, C₁₋₄alkyl
 substituted by HO or C₁₋₃alkoxy, R⁵ is hydrogen, halogen, C₁₋₄alkoxy, nitrile, W is
 hydrogen or C(=O)C₁₋₈alkyl. In preferred embodiments, R¹, R³ and R⁵ are hydrogen, R² is
 methyl, R⁴ is halogen, methyl or trifluoromethyl, and W is hydrogen. Most preferably, the
 15 compounds of the invention have an R-configuration at the carbon atom bearing the
 primary amine.

In another aspect, the present invention provides compositions containing the
 compounds described above in a pharmaceutically acceptable excipient. The compositions
 20 are most preferably in the form of topical ophthalmic formulations for delivery to the eye.
 The compounds of the invention may be combined with ophthalmologically acceptable

preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution to form the compositions of the invention.

5 The compositions of the invention are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 5 to 8. The compounds of the invention as

BLANK PAGE